C4 Therapeutics (CCCC)
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product c...
- Open
- 3.810
- High
- 3.860
- Low
- 3.710
- Prev. Close
- 3.850
- Volume
- 987.92K
- Turnover
- 3.70M
- Avg Price
- 3.747
- Bid/Ask Ratio
- -13.34%
- Amplitude
- 3.90%
- 52wk High
- 5.170
- Volume Ratio
- 0.39
- Turnover Ratio
- 1.05%
C4 Therapeutics Analyst Rating
View moreForecast & Rating
Aug 28, 2026Price forecast
$13.33256.98%
Forecast & RatingStrong buy
7analysts
- Strong buy85.71%
- Buy14.29%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 13 at 06:13 AM
Brokers Set Expectations for C4 Therapeutics Q3 Earnings
- benzinga_article · Aug 11 at 11:58 AM
C4 Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
- PUBT · Aug 10 at 03:01 PM
C4 Therapeutics grants new hire stock options for 162,880 shares under Nasdaq inducement rule
- PUBT · Jun 24 at 03:22 PM
C4 Therapeutics shareholders approve amendment to 2020 stock incentive plan evergreen provision
- rttnews · May 31 at 09:33 PM
Top Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX Soars
- Tip Ranks · May 15 at 04:12 PM
C4 Therapeutics Realigns Finance Leadership After Officer Departure
